PLAU and cancer: With proven good specificity for the uPA/uPAR signaling, another more suitable clinical application for 89Zr-Df-ATN-291 is that it may be used as a screening agent to identify uPA/uPAR profiles in cancer patients and select the appropriate patient population to benefit more from a given uPA-targeted therapeutic.